MedPage Today -- For those who might have lingering doubts, post-hoc analyses of two landmark statin trials -- PROVE-IT and IDEAL -- affirm the value of an intensive versus moderate approach to lipid-lowering, researchers here reported.
MedPage Today -- For those who might have lingering doubts, post-hoc analyses of two landmark statin trials -- PROVE-IT and IDEAL -- affirm the value of an intensive versus moderate approach to lipid-lowering, researchers here reported.